Reimbursement cuts and the future of ICD follow-up care

For many Australians living with an implantable cardioverter-defibrillator, regular device checks are not optional extras but essential touchpoints that keep daily life stable. When policymakers trim the reimbursements that fund these reviews, the impact rarely looks dramatic at first glance, yet the downstream consequences for patients, clinicians and the wider health system can be profound.

Australia's healthcare landscape already wrestles with the geography of a vast continent, a mixed public-private funding model and growing demand for complex cardiac services. Any reduction in the Medicare Benefits Schedule payments that support device interrogation and follow-up consultations risks widening gaps that many electrophysiology teams have spent years working hard to close.

Why consistent device interrogation matters after implantation

An implantable cardioverter-defibrillator, often shortened to ICD, continuously records the electrical activity of the heart, delivers therapy when dangerous rhythms appear and stores diagnostic information that cardiologists rely on for ongoing care. The implanted hardware, however, is only one part of the clinical picture. Battery depletion, lead integrity issues, programming refinements and changes in a patient's underlying heart condition all require periodic in-clinic evaluation or remote transmission review.

Specialist nurses and cardiac physiologists in cities like Sydney, Melbourne and Brisbane typically manage these follow-ups alongside electrophysiologists. A routine review might check capture thresholds, evaluate stored arrhythmia episodes and adjust shock or pacing parameters. When such appointments are postponed or compressed because reimbursement does not keep pace with the time required, subtle device changes can go unnoticed for months. A missed alert about rising defibrillation threshold or progressive battery drain can turn an outpatient visit into an emergency admission.

For patients with heart failure, hypertrophic cardiomyopathy or a history of ventricular arrhythmia, this continuity of surveillance is a cornerstone of secondary prevention. The therapeutic value of an ICD is realised only when the device is functioning optimally and the clinical team can act on the data it provides. Cutting the payments tied to follow-up does not reduce the need for these checks; it simply shifts the burden elsewhere in the system.

How fee schedule reductions ripple through device clinics

Device follow-up is a labour-intensive service. Each in-person review involves technician preparation, device interrogation using manufacturer-specific programmers, clinical assessment and detailed documentation for the patient's medical record. Remote monitoring adds another layer, requiring secure data review, patient communication and escalation protocols when transmissions flag abnormalities.

When reimbursement schedules fail to recognise this complexity, clinics face difficult choices. Some absorb the cost of longer consultations. Others reduce the number of dedicated device clinic sessions per week, lengthening waiting lists. A few shift more patients onto remote monitoring pathways that, while efficient, still demand clinical oversight and infrastructure investment.

The strain is particularly visible in regional centres such as those around Cairns, Toowoomba and Launceston, where small teams already juggle high caseloads. In suburban Perth or Adelaide, private practices sometimes struggle to justify a dedicated cardiac physiologist position once the per-service rebate falls. Over time, the cumulative effect is fewer touchpoints for each patient, less frequent reprogramming and a slow erosion of the safety net the device is supposed to provide.

Geographic and equity challenges across Australia

Australia's size creates unique pressures for cardiac device management. Patients in remote Western Australia, the Northern Territory or far-western Queensland may travel hundreds of kilometres to reach the nearest electrophysiology service. Some rely on retrieval flights coordinated through services that bridge the gap between rural communities and metropolitan hospitals. For these individuals, every device clinic appointment represents a major logistical undertaking.

Indigenous patients in particular face compounded barriers, with cultural safety, language considerations and historical mistrust of mainstream health services layering onto the practical demands of travel. When funding cuts force clinics to consolidate services or lengthen intervals between reviews, remote and Indigenous communities are often the first to feel the impact. The promise of equitable cardiovascular care becomes harder to honour when the financial scaffolding for routine device management weakens.

Different care delivery models respond to these geographic realities in different ways, and each is vulnerable to further cuts in distinct ways.

Care delivery model	Strengths	Limitations	Likely impact of further cuts
Hospital-based device clinic	Integrated with acute services, on-site expertise	Higher overheads, travel burden for patients	Longer waits, reduced session frequency
Private cardiology practice	Convenient for insured patients, flexible scheduling	Capacity limited by rebate economics	Reduced staffing, fewer in-person reviews
Hybrid with remote monitoring	Earlier detection, less travel	Requires IT investment, clinical time unpaid	Underinvestment in transmission review
Outreach visiting model	Auditability, regional reach	Logistically complex, weather dependent	Service contraction in remote areas

Even in metropolitan areas, equity concerns remain. Patients on lower incomes, those without private health insurance and people balancing multiple chronic conditions can find it harder to attend appointments that are rescheduled at short notice. The downstream cost of missed follow-up, including preventable hospitalisations and emergency generator changes, tends to land back on the public system and on the patients themselves.

Technology, policy and the future of remote monitoring

Remote monitoring has transformed how ICD follow-up is delivered. Transmissions sent over secure networks allow clinicians to review device status between clinic visits, identify arrhythmia events and intervene earlier than would otherwise be possible. Many Australian services have embraced this model, supported by professional societies such as the Cardiac Society of Australia and New Zealand.

Yet remote monitoring does not exist in a policy vacuum. Reimbursement frameworks must recognise the clinical time spent reviewing transmissions, communicating with patients and coordinating care. Where fee structures were designed around face-to-face encounters, the shift to remote care can leave revenue lagging behind workload. Without deliberate policy alignment, the very technology that promises better outcomes could be adopted more slowly than evidence supports.

Some clinicians have called for dedicated item numbers for remote device interrogation, similar to arrangements for home sleep studies or ambulatory blood pressure monitoring. Others argue for blended payment models that account for both in-person and remote work. Whatever the mechanism, the goal is the same: ensure that the way devices are monitored keeps pace with how they are used.

Lessons from international experience and pathways forward

The United States has grappled with similar questions around Medicare physician fee schedule adjustments and cardiovascular care, with advocates warning that short-term savings can translate into long-term costs. Australia's mixed funding model, anchored by Medicare and complemented by private insurers and out-of-pocket contributions, offers some insulation, but it also means policy choices in one part of the system can echo through the rest.

Several warning signs should prompt patients or carers to seek earlier follow-up rather than wait for a routine review.

• Sudden change in the number of shocks delivered by the device, including a single shock without warning symptoms.
• Audible alerts, beeps or vibrations from the device that were not present at the previous check.
• New or worsening shortness of breath, dizziness or palpitations between scheduled visits.
• Redness, swelling or discharge around the implant site.
• Missed remote transmissions when the home monitor indicates a connection problem.
• Changes in medications that could affect arrhythmia thresholds or device sensing.

Patients and clinicians can also work together to protect access through several practical strategies.

• Asking the clinic how often follow-up is recommended and confirming that the schedule reflects current guidelines.
• Maintaining a simple log of symptoms, shocks received and any device alerts.
• Travelling with the device identification card and ensuring emergency staff know how to contact the treating team.
• Engaging with consumer representatives who advocate on cardiovascular policy at bodies such as the Consumers Health Forum of Australia.
• Supporting research and policy submissions that document the value of device follow-up, including work that builds on initiatives like this policy proposal guide, which shows how clinical priorities can be translated into formal submissions.

Australia has the clinical expertise, technology and patient advocacy base to keep implantable cardioverter-defibrillator follow-up care accessible, even as funding pressures mount. The conversation must move beyond short-term budget considerations toward a clearer recognition that every avoided follow-up complication is also a hospital admission prevented, a family kept whole and a life extended with dignity.

Readers are encouraged to share their stories with local MPs, contribute to consultations run by the Department of Health and Aged Care, and join national advocacy efforts that highlight the real-world impact of reimbursement decisions on cardiac care. Your voice matters when policies that shape access to life-saving device management are being drafted.